CSL Limited
ASX-CSL
Company Overview
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Name
CSL Limited
CEO
Dr. Paul F. McKenzie Ph.D.
Website
www.csl.com.au
Sector
Biotechnology
Year Founded
1916
Profile
Market Cap
A$145.39B
EV
A$164.22B
Shares Out
484.21M
Revenue
$14.8B
Employees
32,698
Margins
Gross
52.06%
EBITDA
31.2%
Operating
26.32%
Pre-Tax
22.8%
Net
17.85%
FCF
12.94%
Returns (5Yr Avg)
ROA
10.96%
ROTA
42.48%
ROE
23.46%
ROCE
17.42%
ROIC
15.15%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
A$313.66
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$1,657M
Net Debt
$10.53B
Debt/Equity
0.63
EBIT/Interest
8.15
Growth (CAGR)
Rev 3Yr
12.81%
Rev 5Yr
11.63%
Rev 10Yr
10.74%
Dil EPS 3Yr
1.51%
Dil EPS 5Yr
5.22%
Dil EPS 10Yr
7.31%
Rev Fwd 2Yr
6.9%
EBITDA Fwd 2Yr
12.98%
EPS Fwd 2Yr
14.52%
EPS LT Growth Est
13.1%
Dividends
Yield
—
Payout
48.26%
DPS
$2.64
DPS Growth 3Yr
5.95%
DPS Growth 5Yr
7.37%
DPS Growth 10Yr
8.86%
DPS Growth Fwd 2Yr
12.99%